Recurrent Pregnancy Loss

The field of recurrent pregnancy loss (RPL), as it stands today, is riddled with controversies. From its very definition, two versus three miscarriages, and again consecutive versus nonconsecutive losses, there is no consensus among guidelines. The workup required in every couple of RPL and the extended battery of tests that may help to unravel the diagnosis are not yet standardized. Despite guidelines on RPL published by the European Society for Human Reproduction, the American Society of Reproductive Medicine, the Royal College of Obstetricians and Gynaecologists, and many other national bodies, the reader remains confused due to the discrepancy in their recommendations. Being of a multifactorial etiology, the domain of RPL is shared by obstetricians, specialists in assisted reproduction, endoscopists, endocrinologists, and rheumatologists. It is not surprising then that treatment consensus guidelines will need to incorporate evidence-based recommendations from different subspecialist societies, i.e. rheumatology, genetics, endocrinology, and gynecological endoscopy. A large group of women may not identify the cause of recurrent miscarriages. The frustration of both the affected couple and the treating obstetricians leads to rampant use of empirical therapies in unexplained recurrent miscarriages. The aim of the editors is to provide data to minimize this large group of unexplained recurrent miscarriages in the coming decade. Research in this field is also limited by the fact that the number of patients affected by RPL is small and when broken up according to different etiological factors, each center deals with a small number of patients. Hence, to collect data from multicentric studies, the research protocols need to follow standard definitions and diagnostic criteria. This has been lacking so far, hence the paucity of robust data by way of meta-analysis and systematic reviews. The mental well-being of RPL couples has not received due attention, and it is now evident that unresolved stress may be a driver for poor obstetric outcomes. There are no guidelines on quantifying maternal stress and uniform strategies of resolving it.

• On popular demand, we release the fourth edition of this textbook.
• Extensive new research in the subject has led to the addition of 13 new chapters to the book.
• The topics have been divided into various sections based on etiological factors such as genetic, anatomical, infective, and immunological.
• Diagnostic recommendations by the European Society of Human Reproduction and Embryology (ESHRE), the Royal College of Obstetricians and Gynaecologists (RCOG) (UK), and the American College of Obstetrics and Gynecology (ACOG) (USA) and many more
• guidelines have been incorporated. Fetal evaluation by Hyster embryoscopy and genetic evaluation is discussed in detail.
• The section on management is comprehensive, and discusses all new modalities of treatment along with medicolegal implications.
• Role of newer treatment options like hydroxychloroquine (HCQ), immunoglobulin (IVIG), granulocyte colony-stimulating factor (G-CSF), stem cells, in vitro fertilization (IVF)/preimplantation genetic screening (PGS), antioxidants, tacrolimus, and lymphocyte immunotherapy has been elaborated in detail.
• Each chapter is contributed by original researchers in the field from across the world.
• The section on case summaries includes management of difficult cases by experts and adds to better understanding.
• Three complimentary videos as well as a comprehensive resource of further reading has been provided.
• This book will form an comprehensive resource for obstetricians and gynecologists, specialists in reproductive medicine, teaching faculty, and postgraduate students.